Bamco Inc. NY Buys 2,600 Shares in Madrigal Pharmaceuticals

The investment firm added to its position in the biopharmaceutical company in the third quarter.

Mar. 17, 2026 at 7:35am

Got story updates? Submit your updates here. ›

Bamco Inc. NY, a New York-based investment firm, bought a new position of 2,600 shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) during the third quarter, according to a recent SEC filing. The shares were valued at approximately $1.19 million.

Why it matters

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular, metabolic, and liver diseases, with a particular emphasis on nonalcoholic steatohepatitis (NASH). The company's lead product candidate, resmetirom, is in Phase 3 clinical trials for the treatment of NASH, a growing public health concern.

The details

In addition to Bamco Inc. NY's new position, other hedge funds have also been active in trading Madrigal Pharmaceuticals shares. Universal Beteiligungs und Servicegesellschaft mbH increased its stake by 388.3% during the third quarter, while Voya Investment Management LLC grew its holdings by 16.3% in the same period. Calamos Advisors LLC and Marex Group plc also acquired new positions in the company.

  • Bamco Inc. NY bought the 2,600 shares of Madrigal Pharmaceuticals in the third quarter of 2026.

The players

Bamco Inc. NY

A New York-based investment firm that bought a new position of 2,600 shares in Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular, metabolic, and liver diseases, including nonalcoholic steatohepatitis (NASH).

Universal Beteiligungs und Servicegesellschaft mbH

A hedge fund that increased its stake in Madrigal Pharmaceuticals by 388.3% during the third quarter.

Voya Investment Management LLC

A hedge fund that grew its holdings in Madrigal Pharmaceuticals by 16.3% in the third quarter.

Calamos Advisors LLC

A hedge fund that acquired a new position in Madrigal Pharmaceuticals.

Marex Group plc

A hedge fund that acquired a new position in Madrigal Pharmaceuticals.

Got photos? Submit your photos here. ›

The takeaway

Madrigal Pharmaceuticals' lead drug candidate, resmetirom, is a promising treatment for NASH, a growing public health concern. The increased investment activity by hedge funds in the company's stock suggests that the market sees potential in Madrigal's pipeline and the company's ability to address unmet medical needs in this area.